A brief overview of the key points discussed during a company’s quarterly earnings call, including financial performance, guidance, and management’s commentary on future outlook.
Shanghai Medicilon Earnings
Estimates
Actual
Y-on-Y Change
Revenue
EPS
Transcripts
Events
About Shanghai Medicilon Inc.
Shanghai Medicilon Inc.
688202
Shanghai Medicilon Inc., a drug discovery contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. It offers chemistry services, including medicinal, synthesis, and analytical chemistry services, as well as process development services; and drug formulation services, such as pre-formulation and analytical development services, as well as research on quality control and clinical trial material services. The company also provides biology services comprising recombinant protein, crystallization and structural, discovery biology, computational biology and molecular modeling, and kinase services, as well as prepackaged M9 selenomethionine growth media kits and packages for growing cell culture in IPTG-inducible bacterial expression systems. In addition, it offers pharmacology services, including cancer xenograft, metabolic disease, inflammation and immunological, neurological disorders, and other disease models; services in the areas of in vitro ADME and in vivo pharmacokinetics; and bioanalytical services, such as large and small molecule services. Further, the company provides preclinical services comprising preclinical pharmacokinetic and safety evaluation. Shanghai Medicilon Inc. was founded in 2004 and is headquartered in Shanghai, China.
Shanghai Medicilon Inc., a drug discovery contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. It offers chemistry services, including medicinal, synthesis, and ana...
Shanghai Medicilon Inc., a drug discovery contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. It offers chemistry services, including medicinal, synthesis, and analytical chemistry services, as well as process development services; and drug formulation services, such as pre-formulation and analytical development services, as well as research on quality control and clinical trial material services. The company also provides biology services comprising recombinant protein, crystallization and structural, discovery biology, computational biology and molecular modeling, and kinase services, as well as prepackaged M9 selenomethionine growth media kits and packages for growing cell culture in IPTG-inducible bacterial expression systems. In addition, it offers pharmacology services, including cancer xenograft, metabolic disease, inflammation and immunological, neurological disorders, and other disease models; services in the areas of in vitro ADME and in vivo pharmacokinetics; and bioanalytical services, such as large and small molecule services. Further, the company provides preclinical services comprising preclinical pharmacokinetic and safety evaluation. Shanghai Medicilon Inc. was founded in 2004 and is headquartered in Shanghai, China.
Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach. Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.